https://www.patientcareonline.com/view/natalizumab-tysabri-reduces-vision-loss-ms
Natalizumab (Tysabri) Reduces Vision Loss in MS | Patient Care Online
Oct 15, 2026 - PHILADELPHIA -- Natalizumab (Tysabri), which reduces relapse rates in patients with relapsing multiple sclerosis, also prevents vision loss, researchers here...
vision losspatient carenatalizumabtysabrireduces
https://almclinmed.ru/jour/article/view/352
A COMPARATIVE ANALYSIS OF EFFICACY OF INTERFERON BETA 1-B AND NATALIZUMAB TREATMENT IN PATIENTS...
A COMPARATIVE ANALYSIS OF EFFICACY OF INTERFERON BETA 1-B AND NATALIZUMAB TREATMENT IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
comparative analysisinterferon betaefficacynatalizumabtreatment
https://iris.uniroma1.it/handle/11573/484210
Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab
glatiramer acetateeffectdiseasereactivationpatients
https://diariofarma.com/2019/09/05/sandoz-comercializara-el-biosimilar-de-natalizumab-desarrollado-por-polpharma
Sandoz comercializará el biosimilar de natalizumab desarrollado por Polpharma | @diariofarma
Dec 15, 2019 - Sandoz ha anunciado que ha formalizado un acuerdo global de comercialización para el biosimilar propuesto de natalizumab con la compañía polaca Polpharma...
desarrollado porsandozbiosimilarnatalizumabpolpharma